Study title:
A randomized, placebo-controlled trial, to evaluate the safety and immunogenicity of the COVID-19 vaccine, a measles vector-based vaccine candidate against COVID-19 in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment p
Long title:
A randomized, placebo-controlled trial, to evaluate the safety and immunogenicity of the COVID-19 vaccine, a measles vector-based vaccine candidate against COVID-19 in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment phase.
Date receipt dossier:
22 Jun 2020
EU record number:
COVID-19-101
EudraCT number:
2020-002973-89
Pharmaceutical study code:
MV-SARS-Cov2
Company / Sponsor:
Institut Pasteur & Themis Bioscience GmbH
Phase:
I
Treated organism:
Humans
Indication category:
Infectious disease
Disease:
COVID-19
Therapeutic approach:
Prevention
Genetic modification:
Recombinant measles virus vaccine strain (Schwarz strain) expressing the Spike glycoprotein 1 from SARS-CoV2
Method of transfer of nucleic acid of interest:
Not applicable
Administered biological material:
Recombinant measles virus vaccine strain (Schwarz strain) expressing the Spike glycoprotein 1 from SARS-CoV2
Route of administration:
Intramuscular
Locations in Belgium:
SGS Belgium
Type of procedure:
Contained use only
Current status:
Under evaluation